Mylan N.V. (NASDAQ: MYL) is a large market cap stock with a market cap of 21572.24. It is in the Drugs – Generic industry and sector Healthcare, with a current P/E of 27.28, a forward P/E of 7.28 and EPS of 1.56. At a stock price of 42.67 (-1.86%) it has a dividend yield of *TBA.
EPS growth for the last five years have been 20.20%, more recently this last year it has grown by -31.50%. The next year growth is going to be about 18.56% and more long-term 13.98% after five years. EPS growth quarter over quarter is -78.60%. Sales growth for the past five years have been 11.60% and sales growth quarter over quarter is 17.10%.
For performance, Mylan N.V. the past week has seen a gain of 2.06%. For the last month performance for Mylan N.V. is -4.16%. While the last quarter is -7.08% and half year, -19.91%. Finally for the year, performance is -39.69%.
The 52-week high for Mylan N.V., is at -42.26%, and for the 52-week low it comes to a value of 13.51%. The 20-day simple moving average is -1.46% and -8.69% for the 200-day simple moving average.
Volatility for the week is at 2.27%, and for the month it is 2.81%. Mylan N.V., has a target price of 58.13.
In terms of debt, long term debt/equity is 0.62, and for total debt/equity Mylan N.V. has 0.73. The gross margin is 44.50%, while operating margin is 14.60%, the profit margin is 8.30%. The current ratio is 1.7 and the quick ratio is 1.1.
Insider ownership is at 0.70%, with instituitional ownership at 71.30%. Mylan N.V. has a payout ratio of 0.00%. With the total shares outstanding coming to 505.56. The shares float is 412.23, with the float short at 6.27%, with short ratio coming to 5.09.
In terms of returns, the return on assets see Mylan N.V., get 3.60%, with its returns on investment at 8.20%. Return on equity is 8.20%. So will the investors see the target price of 58.13, reached soon?
Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.